Journal
FRONTIERS IN PSYCHIATRY
Volume 10, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fpsyt.2019.00605
Keywords
depression; bipolar disorder; schizophrenia; obsessive compulsive disorder; autism spectrum disorder; psychiatry; inflammation; cyclooxygenase-2 inhibitors
Categories
Funding
- Stanley Medical Research Foundation NIH
- MBF
- NHMRC
- NHMRC Senior Principal Research Fellowship [APP1059660, APP1156072]
- Cooperative Research Centre
- Simons Autism Foundation
- Cancer Council of Victoria
- Rotary Health
- Meat and Livestock Board Woolworths
- BeyondBlue
- Geelong Medical Research Foundation Bristol Myers Squibb
- Eli Lilly
- Glaxo SmithKline
- Organon
- Novartis
- Mayne Pharma
- Servier
- Trisno Family Fellowship
Ask authors/readers for more resources
Neuropsychiatric disorders, such as depression, bipolar disorder, schizophrenia, obsessive-compulsive disorder, and neurodevelopmental disorders such as autism spectrum disorder, are associated with significant illness burden. Accumulating evidence supports an association between these disorders and inflammation. Consequently, anti-inflammatory agents, such as the cyclooxygenase-2 inhibitors, represent a novel avenue to prevent and treat neuropsychiatric illness. In this paper, we first review the role of inflammation in psychiatric pathophysiology including inflammatory cytokines' influence on neurotransmitters, the hypothalamic-pituitary-adrenal axis, and microglial mechanisms. We then discuss how cyclooxygenase-2-inhibitors influence these pathways with potential therapeutic benefit, with a focus on celecoxib, due to its superior safety profile. A search was conducted in PubMed, Embase, and PsychINFO databases, in addition to Clinicaltrials.gov and the Stanley Medical Research Institute trial registries. The results were presented as a narrative review. Currently available outcomes for randomized controlled trials up to November 2017 are also discussed. The evidence reviewed here suggests cyclooxygenase-2 inhibitors, and in particular celecoxib, may indeed assist in treating the symptoms of neuropsychiatric disorders; however, further studies are required to assess appropriate illness stage-related indication.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available